Overview

Phase Ib/II Trial of RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Status:
Not yet recruiting
Trial end date:
2027-08-15
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in R/R CLL patients with DDR deficiencies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Utah
Collaborator:
Repare Therapeutics
Treatments:
Olaparib